Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:KROS NASDAQ:MNMD NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.85+1.8%$1.82$0.73▼$3.90$177.22M0.7417,156 shs204,499 shsKROSKeros Therapeutics$14.49+1.7%$13.99$9.12▼$72.37$578.77M1.26861,626 shs377,232 shsMNMDMind Medicine (MindMed)$8.58+6.3%$7.20$4.70▼$10.44$609.71M2.451.32 million shs1.28 million shsTLRYTilray Brands$0.60+1.6%$0.46$0.35▼$2.15$597.15M1.8231.10 million shs23.24 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+1.79%+26.67%+91.28%+106.52%+13.10%KROSKeros Therapeutics+1.68%+1.19%+6.08%+2.99%-72.23%MNMDMind Medicine (MindMed)+6.32%+11.14%+20.17%+48.70%+1.06%TLRYTilray Brands+1.58%-10.72%+42.65%+33.93%-68.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGALTGalectin Therapeutics2.2682 of 5 stars3.52.00.00.03.31.70.0KROSKeros Therapeutics2.0858 of 5 stars3.31.00.00.02.73.30.0MNMDMind Medicine (MindMed)2.1082 of 5 stars3.61.00.00.02.90.80.6TLRYTilray Brands1.8538 of 5 stars3.11.00.00.03.20.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 3.00Buy$6.00110.53% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.56110.87% UpsideMNMDMind Medicine (MindMed) 3.27Buy$25.50197.20% UpsideTLRYTilray Brands 2.25Hold$1.92218.01% UpsideCurrent Analyst Ratings BreakdownLatest GALT, KROS, TLRY, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AKROSKeros Therapeutics$3.55M165.80N/AN/A$14.11 per share1.03MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ATLRYTilray Brands$788.94M0.77N/AN/A$4.14 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)KROSKeros Therapeutics-$187.35M-$0.18N/AN/AN/A1.96%0.75%0.69%8/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)TLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest GALT, KROS, TLRY, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GALTGalectin Therapeutics-$0.16N/AN/AN/AN/AN/A8/12/2025Q2 2025MNMDMind Medicine (MindMed)-$0.37N/AN/AN/AN/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.13N/AN/AN/A$3.83 millionN/A8/4/2025Q4 2025TLRYTilray Brands-$0.03N/AN/AN/AN/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A0.080.08KROSKeros TherapeuticsN/A19.2919.29MNMDMind Medicine (MindMed)0.107.277.27TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%KROSKeros Therapeutics71.56%MNMDMind Medicine (MindMed)27.91%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics50.10%KROSKeros Therapeutics20.60%MNMDMind Medicine (MindMed)2.45%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableGALT, KROS, TLRY, and MNMD HeadlinesRecent News About These CompaniesTilray (TLRY) Stock Is Up, What You Need To KnowJuly 16 at 3:15 PM | msn.comTilray Brands (NASDAQ:TLRY) Shares Up 4% - What's Next?July 16 at 1:29 PM | marketbeat.comTilray Brands (NasdaqGS:TLRY) Soars 44% In Last MonthJuly 15 at 9:46 PM | finance.yahoo.comTilray (TLRY) Shares Skyrocket, What You Need To KnowJuly 15 at 9:46 PM | msn.comTilray Brands (NASDAQ:TLRY) Trading Down 6.2% - What's Next?July 15 at 3:20 PM | marketbeat.comTilray Brands stock price is surging: time to buy or sell?July 15 at 11:39 AM | invezz.comITilray Brands stock price is surging: time to buy or sell?July 15 at 11:01 AM | invezz.comIUp Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher?July 15 at 9:45 AM | fool.comTilray Shares Blazing: What's Behind the 55% Rally This Month?...July 14 at 4:40 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 7% - Here's What HappenedJuly 14 at 3:36 PM | marketbeat.comTilray Brands, Inc. (TLRY) Declines More Than Market: Some Information ...July 13, 2025 | finance.yahoo.comCannabis Stocks To Follow Today - July 13thJuly 13, 2025 | marketbeat.comPromising Cannabis Stocks To Follow Now - July 12thJuly 12, 2025 | marketbeat.comTilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for InvestorsJuly 11, 2025 | zacks.comTop Cannabis Stocks To Watch Today - July 11thJuly 11, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading Down 5.4% - Should You Sell?July 11, 2025 | marketbeat.com3 Marijuana Stocks To Watch: Key Trends Driving Cannabis Industry GrowthJuly 11, 2025 | marijuanastocks.comMTilray Brands (NASDAQ:TLRY) Trading Down 3.1% - Should You Sell?July 10, 2025 | marketbeat.comPromising Cannabis Stocks To Watch Now - July 10thJuly 10, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 14.5% - Here's WhyJuly 9, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Sees Large Volume Increase - Should You Buy?July 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?GALT, KROS, TLRY, and MNMD Company DescriptionsGalectin Therapeutics NASDAQ:GALT$2.85 +0.05 (+1.79%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.81 -0.04 (-1.54%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Keros Therapeutics NASDAQ:KROS$14.49 +0.24 (+1.68%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$14.82 +0.32 (+2.24%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Mind Medicine (MindMed) NASDAQ:MNMD$8.58 +0.51 (+6.32%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$8.57 -0.01 (-0.06%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Tilray Brands NASDAQ:TLRY$0.60 +0.01 (+1.58%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$0.61 +0.00 (+0.71%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
